Ipamorelin + CJC-1295 (no DAC)
One of the most commonly discussed two-peptide research pairings, combining a selective ghrelin-receptor agonist with a GHRH analog to stimulate growth hormone release through two complementary receptor pathways.
Rationale
Complementary GH-stimulating mechanisms (GHRH analog + GHS-R agonist). Popular pairing anecdotally; not supported by controlled human outcome trials.
Ipamorelin
Selective ghrelin-receptor (GHS-R1a) agonist that stimulates pulsatile GH release with minimal effect on cortisol/prolactin.
Typically dosed together with CJC-1295 (no DAC) at the same injection time in research protocols, though each peptide is dosed according to its own studied range.
Animal GH-release studies (potency reference)
- Frequency
- single-dose pharmacology
Commonly cited non-clinical use range — NOT validated
- Dose
- 200–300 mcg
- Frequency
- 1-3x daily (anecdotal)
CJC-1295 (no DAC)
GHRH analog that extends the amplitude/duration of GH pulses; commonly paired with a GHRP/ghrelin-receptor agonist like ipamorelin for a synergistic release pattern.
Commonly cited non-clinical use range (no-DAC) — NOT validated
- Dose
- 100–200 mcg
- Frequency
- 1-3x daily (anecdotal)
For research and educational purposes only. This is not medical advice. Neither peptide is FDA-approved. Consult a licensed healthcare provider before using any peptide.